Page last updated: 2024-12-10

xanthatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

xanthatin: a phytogenic antineoplastic agent; RN given refers to (3aR-(3aalpha,7beta,8abeta))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281511
CHEBI ID10058
MeSH IDM0077917

Synonyms (25)

Synonym
26791-73-1
xanthatin
chebi:10058 ,
(3ar,7s,8as)-7-methyl-3-methylidene-6-[(e)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3ah-cyclohepta[b]furan-2-one
unii-298x1n12ls
3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-(3-oxo-1-butenyl)-2h-cyclohepta(b)furan-2-one
298x1n12ls ,
2h-cyclohepta(b)furan-2-one, 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-((1e)-3-oxo-1-buten-1-yl)-, (3ar,7s,8as)-
xanthatin, (-)-
xanthatin [mi]
(-)-xanthatin
AC-34070
bdbm233119
xanthatin (2)
AKOS037514876
HY-N3032
(3ar,7s,8as)-7-methyl-3-methylene-6-((e)-3-oxobut-1-en-1-yl)-3,3a,4,7,8,8a-hexahydro-2h-cyclohepta[b]furan-2-one
mfcd17214852
Q27108568
CS-0023046
BS-50231
A877137
(3ar,7s,8as)-7-methyl-3-methylidene-6-[(1e)-3-oxobut-1-en-1-yl]-2h,3h,3ah,4h,7h,8h,8ah-cyclohepta[b]furan-2-one
DTXSID001317668
BBA79173

Research Excerpts

Overview

Xanthatin is a plant-derived bioactive sesquiterpene lactone from the Xanthium strumarium L. It has been used as a traditional Chinese medicine.

ExcerptReferenceRelevance
"Xanthatin is a plant-derived bioactive sesquiterpene lactone from the Xanthium strumarium L., and it has been used as a traditional Chinese medicine. "( TMT-Based Quantitative Proteomic Analysis Identified Proteins and Signaling Pathways Involved in the Response to Xanthatin Treatment in Human HT-29 Colon Cancer Cells.
Chen, Z; Geng, Y; Li, L; Liu, P; Shen, A; Zhang, L, 2022
)
2.37
"Xanthatin is an active sesquiterpene lactone isolated from Xanthium strumarium L."( Xanthatin inhibits non-small cell lung cancer proliferation by breaking the redox balance.
Geng, Y; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhu, X, 2022
)
2.89
"Xanthatin (XT) is a sesquiterpene lactone isolated from the Chinese herb Xanthium, which belongs to the Asteraceae family. "( Xanthatin Alleviates LPS-Induced Inflammatory Response in RAW264.7 Macrophages by Inhibiting NF-κB, MAPK and STATs Activation.
Chen, W; Liu, Y; Wei, K; Yu, H; Zheng, F, 2022
)
3.61
"Xanthatin is a sesquiterpene lactone monomer compound purified from the traditional Chinese herb Xanthium strumarium L."( Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights.
Geng, Y; Hou, X; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhang, X, 2023
)
3.07
"Xanthatin (XT) is a bioactive compound derived from Xanthium strumarium L, and we developed a polymeric micelle (PM) that is dendritic cells (DCs)-specific targeting delivery system loading XT (NGR-XT-PM) based on a cyclic peptide moiety (NGR) to render DCs maturation-resistant for therapy of refractory AR."( CD13-specific ligand facilitates Xanthatin nanomedicine targeting dendritic cells for therapy of refractory allergic rhinitis.
Chu, X; Liu, C; Sun, C; Wang, C; Xia, M; Xu, J; Xu, X; Yu, R; Zhao, M; Zheng, X, 2020
)
1.56
"Xanthatin (Xa) is a bicyclic sesquiterpene lactone identified from the plant Xanthium L. "( Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells.
Gao, Y; Guan, H; Yang, S; Zhang, J; Zhou, J, 2021
)
3.51
"Xanthatin is an active sesquiterpene lactone isolated from Xanthium strumarium L."( Xanthatin inhibits human colon cancer cells progression via mTOR signaling mediated energy metabolism alteration.
Chen, Z; Geng, Y; Li, L; Liu, P; Liu, Y; Xie, Y; Zhang, L, 2022
)
2.89

Actions

ExcerptReferenceRelevance
"Xanthatin may inhibit the proliferation of pancreatic cancer cells and trigger apoptosis through the ROS/RBL1 signaling pathway."( Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights.
Geng, Y; Hou, X; Liu, P; Liu, Y; Xie, Y; Zhang, L; Zhang, X, 2023
)
3.8

Treatment

ExcerptReferenceRelevance
"The xanthatin treatment group exhibited a lower protein expression level of VEGF and increased protein expression level of PEDF, compared with the PBS treatment group."( Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
Jiang, N; Ma, MY; Shao, Y; Shen, M; Shi, C; Yang, QC; Ye, L; Yuan, Q; Zhou, XZ; Zhu, PW, 2018
)
2.4

Pharmacokinetics

ExcerptReferenceRelevance
"A sensitive, specific and rapid ultra high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method has been established to study pharmacokinetic properties of xanthatin."( Determination of xanthatin by ultra high performance liquid chromatography coupled with triple quadrupole mass spectrometry: application to pharmacokinetic study of xanthatin in rat plasma.
Cai, B; Chen, Z; Li, H; Li, W; Liu, X; Weng, Z; Wu, Y; Xie, D; Yan, C, 2014
)
0.93

Bioavailability

ExcerptReferenceRelevance
" Eventually, the bioavailability of XA was increased."( A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin.
Chen, R; Chen, Z; Li, W; Lin, S; Wu, L; Zhou, Y; Zhu, C; Zhu, X, 2020
)
0.78

Dosage Studied

ExcerptRelevanceReference
" Solid oral dosage forms based on xanthatin were designed and assayed on rats."( Determination and assay validation of the bioactive sesquiterpene lactone xanthatin isolated from Xanthium cavanillesii using capillary electrophoresis.
Acosta, G; Favier, LS; Gomez, MR; María, AO; Tonn, CE, 2006
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpene lactoneAny member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency6.58420.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency6.58420.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID321377Inhibition of iNOS expression in LPS-stimulated mouse BV2 cells at 20 uM after 20 hrs by Western blot analysis2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321376Inhibition of NO production in LPS-activated mouse BV2 cells by ELISA2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321379Inhibition of iNOS mRNA expression in LPS-stimulated mouse BV2 cells at 20 uM after 4 hrs by RT-PCR2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321378Inhibition of COX2 expression in LPS-stimulated mouse BV2 cells after 20 hrs by Western blot analysis2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321382Inhibition of NF-kappaB activity in LPS-stimulated mouse BV2 cells at 10 uM after 1 hr by luciferase reporter gene assay2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321381Inhibition of IkappaB alpha degradation in LPS-induced mouse BV2 cells at 20 uM after 30 mins by Western blot analysis2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID321380Inhibition of COX2 mRNA expression in LPS-stimulated mouse BV2 cells at 20 uM after 4 hrs by RT-PCR2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium.
AID1802940Fluorescence-Based PFTase Inhibition Assay from Article 10.3109/14756360903169592: \\Semisynthesis of alpha-methyl-gamma-lactones and in vitro evaluation of their activity on protein farnesyltransferase.\\2010Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 25, Issue:2
Semisynthesis of alpha-methyl-gamma-lactones and in vitro evaluation of their activity on protein farnesyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.70)18.7374
1990's2 (3.70)18.2507
2000's6 (11.11)29.6817
2010's25 (46.30)24.3611
2020's19 (35.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.03 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index5.38 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (98.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]